Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 7Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Hepatocellular 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Cisplatin 27Gemcitabine 22toripalimab 19Radiotherapy, Intensity-Modulated 18Capecitabine 10Radiotherapy 8Magnetic Resonance Spectroscopy 8nimotuzumab 7camrelizumab 7Specimen Handling 7Immune Checkpoint Inhibitors 7spartalizumab 5Drug Therapy 5Docetaxel 5Nivolumab 4Biopsy 4sintilimab 3Surgical Procedures, Operative 3Radiosurgery 3Platinum 3Fluorouracil 3Endoscopy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tislelizumab 2pembrolizumab 2irinotecan sucrosofate 2envafolimab 2apatinib 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Carcinoma × apatinib × Clear all
NCT06438627 2024-07-16

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Sun Yat-sen University

Phase 3 Recruiting
164 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Sun Yat-sen University

Phase 3 Recruiting
244 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡